• High-Throughput BBB Screening with LLC-PK1-MDR1

  2026-08-21

  Hu and colleagues developed a Transwell surrogate blood-brain barrier model combining LLC-PK1-MOCK and LLC-PK1-MDR1 cells with a correction for lysosomal trapping. Across 41 compounds, the platform linked in vitro permeability to in vivo unbound brain distribution and provided a scalable approach for prioritizing CNS drug candidates.

• Single-Cell RNA Isoforms in Alzheimer’s Disease

  2026-08-21

  This study combines 10X Genomics single-nucleus profiling with PacBio Kinnex long-read sequencing to resolve full-length RNA isoforms in post-mortem Alzheimer’s disease and non-diseased human cortex. The findings show extensive cell-type-specific isoform diversity, disease-associated transcript changes, and isoform switching that are not readily captured by conventional short-read approaches.

• 15-PGDH Inhibition and Muscle Recovery During Weight Loss

  2026-08-20

  This 2026 PNAS study identifies 15-PGDH inhibition as a strategy for improving muscle repair and force recovery during semaglutide-associated weight loss in obese mice. The work separates successful body-weight reduction from preservation of regenerative muscle quality, showing that combined treatment enhances muscle stem cell activity and regenerated myofiber growth without weakening semaglutide’s weight-loss effect.

• 4μ8C Workflows for IRE1α ER Stress Research

  2026-08-20

  Use 4μ8C to separate IRE1α RNase signaling from broad ER-stress toxicity in hypoxia, cancer, and mechanistic UPR experiments. This practical guide connects fresh-solution handling, pathway-specific readouts, and TBK1-focused assay design without overstating what this preclinical tool can prove.

• CDK4, 4E-BP1, and Chemoproteomic Kinase Mapping

  2026-08-19

  Mitchell, Menon, and Garner introduced PhAXA, a phosphorylation-site-aware chemoproteomic strategy for assigning kinase–substrate relationships. Applying it to cancer signaling revealed that CDK4 phosphorylates 4E-BP1, helping sustain cap-dependent translation and c-Myc expression during mTORC1-inhibitor treatment.

• NADH Workflows for Redox and Mitochondrial Research

  2026-08-19

  Build reproducible NADH experiments that connect redox state with mitochondrial function, disease modeling, and photocatalytic chemistry. This practical guide combines fresh-solution handling, NADH/NAD⁺ measurements, mechanistic controls, and troubleshooting strategies for cell-based workflows.

• Shionone and PINK1-Parkin Mitophagy in Pulmonary Fibrosis

  2026-08-18

  A 2026 study identifies PINK1-Parkin-mediated mitophagy as a mechanistic link between shionone treatment and reduced pulmonary fibrosis. Using bleomycin-induced fibrosis in mice and TGF-β-stimulated A549 cells, the authors connect mitochondrial quality control with lower oxidative stress, extracellular matrix accumulation, and fibrotic signaling.

• Thiamet G for O-GlcNAc Research Workflows

  2026-08-18

  Thiamet G enables controlled elevation of protein O-GlcNAcylation across neuronal, cancer, and placental stress models. This workflow-focused guide covers dose selection, mechanistic readouts, translational use cases, and troubleshooting for more reproducible O-GlcNAcase inhibition experiments.

• Recombinant Human EGF: Migration Assay Workflows

  2026-08-17

  Learn how recombinant human EGF can be integrated into quantitative migration, proliferation, and signaling assays. This workflow emphasizes dose control, matched controls, and the important distinction between EGF-driven migration and true invasive or EMT-associated behavior.

• Imidazoline Antagonists and β-Cell K+ Channels

  2026-08-16

  Jonas, Plant, and Henquin showed that several imidazoline α2-adrenoceptor antagonists stimulate insulin release primarily by inhibiting ATP-sensitive K+ channels in mouse pancreatic β-cells. By combining 86Rb efflux, diazoxide and clonidine challenge experiments, and whole-cell patch clamp, the study separated channel-mediated effects from conventional adrenergic receptor antagonism.

• Ibotenic Acid Workflows for Neurodegeneration

  2026-08-15

  Build more reproducible glutamatergic injury and circuit-modeling studies with Ibotenic acid, from fresh solution preparation through behavioral, biochemical, and histological readouts. This guide translates dose- and time-dependent toxicity findings into practical assay design, controls, and troubleshooting decisions for preclinical neuroscience.

• Pexmetinib (ARRY-614): Reading Kinase-State Data

  2026-08-15

  Pexmetinib (ARRY-614) is a dual p38 MAPK and Tie2 inhibitor for investigating inflammatory cytokine inhibition and hematologic disease biology. This article explains how kinase conformational state, phosphatase activity, and assay timing can change the interpretation of cytokine and phospho-p38 readouts.

• Cross-Talking Regulators in A40926 Biosynthesis

  2026-08-14

  The reference study shows that pathway-specific regulators controlling teicoplanin and A40926 biosynthesis are not functionally interchangeable simply because they are related by sequence. Reciprocal regulator-complementation experiments identify a stronger degree of compatibility among LuxR-like regulators than among StrR-like regulators, while also revealing a route for improving glycopeptide antibiotic production.

• Sulfachloropyridazine: DHPS Research Guide

  2026-08-14

  Sulfachloropyridazine is a sulfonamide antibacterial agent used to study bacterial folate-pathway inhibition, antimicrobial susceptibility, and microbiota responses. Its reported activity against dihydropteroate synthase and its effects in an Eimeria tenella chicken model support applications in enzyme inhibition assay design and microbial ecology studies.

• Cytochalasin D for Corneal Nanoparticle Uptake

  2026-08-13

  Use Cytochalasin D as a controlled actin polymerization inhibitor to distinguish nanoparticle binding from energy-dependent internalization in human corneal epithelial cells. The workflow combines mechanism-focused uptake experiments with viability, morphology, and formulation controls for more interpretable ocular drug-delivery data.

449 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page